VHL Antibody

Polyclonal Antibody

VHL

Elongin binding protein antibody, G7 protein antibody, HRCA 1 antibody, HRCA1 antibody, Protein G7 antibody, pVHL antibody, RCA 1 antibody, RCA1 antibody, VHL 1 antibody, VHL antibody, VHL_HUMAN antibody, VHL1 antibody, VHLH antibody, Von Hippel Lindau antibody, Von Hippel Lindau disease tumor suppressor antibody, von Hippel Lindau syndrome antibody, von Hippel Lindau tumor suppressor antibody, Von Hippel Lindau tumor suppressor, E3 ubiquitin protein ligase antibody, Von Hippel-Lindau disease tumor suppressor antibody

Fusion protein of human VHL

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Antigen Affinity Purified

Cell Biology

Fusion protein of Human VHL